In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Jackson, Dowdy ^a   Atkinson, John ^a   Guevara, Claudia I ^a   Zhang, Chunying ^a   Kery, Vladimir ^a   Moon, Sung Ju ^a   Virata, Cyrus ^a   Yang, Peng ^a   Lowe, Christine ^a   Pinkstaff, Jason ^b   Cho, Ho ^b   Knudsen, Nick ^b   Manibusan, Anthony ^b   Tian, Feng ^b   Sun, Ying ^b   Lu, Yingchun ^b   Sellers, Aaron ^b   Jia, Xiao Chi ^a   Joseph, Ingrid ^a   Anand, Banmeet ^a   Morrison, Kendall ^a   Pereira, Daniel S ^a   Stover, David ^a   more..

^a Agensys Inc   (United States)

^b AMBRX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETYL PHENYLALANINE; ANTIBODY DRUG CONJUGATE; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; PHENYLALANINE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TOXICITY TESTING; TUMOR CELL LINE;

EID: 84898005371     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083865     Document Type: Article

References (19)

1. Goldmacher VS, Kovtun YV (2011) Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv 2: 397-416.
2. Meden H, Kuhn W (1997) Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol 71: 173-179. (Pubitemid 27067265)
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-182. (Pubitemid 17231334)
4. Papazisis KT, Habeshaw T, Miles DW (2004) Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. Int J Clin Pract 58: 581-586. (Pubitemid 38996987)
5. Hurvitz SA, Kakkar R (2012) The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Ther Adv Med Oncol 4: 235-245.
6. Hubalek M, Brunner C, Mattha K, Marth C (2010) Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien Med Wochenschr 160: 506-512.
7. Barok M, Tanner M, Koninki K, Isola J (2011) Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 13: R46.
8. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, et al. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68: 9280-9290.
9. Guha M (2012) T-DM1 impresses at ASCO. Nat Biotech 30: 728-728.
10. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, et al. (2010) Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 16: 4769-4778.
11. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, et al. (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A.
12. Iman WJ, Ca RL (1981) Rank transformations as a bridge between parametric and nonparametric statistics. The American Statistician 35: 124-129.
13. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, et al. (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261: 212-215. (Pubitemid 23265398)
14. Valliere-Douglass JF, McFee WA, Salas-Solano O (2012) Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues. Anal Chem 84: 2843-2849.
15. Xu K, Liu L, Saad OM, Baudys J, Williams L, et al. (2011) Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem 412: 56-66.
16. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, et al. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10: 7063-7070. (Pubitemid 39383058)
17. Crisalli P, Kool ET (2013) Water-soluble organocatalysts for hydrazone and oxime formation. J Org Chem 78: 1184-1189.
18. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, et al. (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30: 184-189.
19. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, et al. (2013) SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122: 1455-1463.